A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Public ClinicalTrials.gov record NCT04281472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
Study identification
- NCT ID
- NCT04281472
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 322 participants
Conditions and interventions
Interventions
- efgartigimod PH20 SC in stage B Biological
- placebo in stage B Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2020 (Actual)
- Primary completion
- May 11, 2023 (Actual)
- Completion
- May 11, 2023 (Actual)
- Last update posted
- Aug 20, 2024
2020 – 2023
United States locations
- U.S. sites
- 45
- U.S. states
- 21
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator site 0010065 | Birmingham | Alabama | 35233-2110 | — |
| Investigator site 0010013 | Phoenix | Arizona | 85018 | — |
| Investigator site 0010055 | Scottsdale | Arizona | 85028 | — |
| Investigator Site 0010032 | Carlsbad | California | 92011 | — |
| Investigator site 0010004 | Orange | California | 92868 | — |
| Investigator site 0010190 | Pomona | California | 91767-2009 | — |
| Investigator site 0010160 | Rancho Mirage | California | 92270 | — |
| Investigator site 0010071 | San Francisco | California | 94109 | — |
| Investigator site 0010057 | Centennial | Colorado | 80112 | — |
| Investigator site 0010026 | New Haven | Connecticut | 06520 | — |
| Investigator site 0010072 | Boca Raton | Florida | 33487 | — |
| Investigator site 0010144 | Coral Springs | Florida | 33067-4640 | — |
| Investigator site 0010023 | Jacksonville | Florida | 32209 | — |
| Investigator Site 0010068 | Maitland | Florida | 32751 | — |
| Investigator site 0010059 | Miami | Florida | 33136 | — |
| Investigator site 0010050 | Orlando | Florida | 32806 | — |
| Investigator site 0010172 | Ormond Beach | Florida | 32174-3102 | — |
| Investigator site 0010006 | Tampa | Florida | 33612 | — |
| Investigator site 0010125 | Augusta | Georgia | 30912-3125 | — |
| Investigator site 0010011 | Iowa City | Iowa | 52242 | — |
| Investigator site 0010015 | Fairway | Kansas | 66205 | — |
| Investigator site 0010147 | Lexington | Kentucky | 40536 | — |
| Investigator site 0010014 | Detroit | Michigan | 48201 | — |
| Investigator site 0010063 | East Lansing | Michigan | 48824 | — |
| Investigator site 0010052 | Minneapolis | Minnesota | 55455-4800 | — |
| Investigator site 0010028 | Columbia | Missouri | 65212 | — |
| Investigator site 0010070 | New Brunswick | New Jersey | 08550 | — |
| Investigator site 0010069 | New York | New York | 06511 | — |
| Investigator site 0010168 | New York | New York | 10001 | — |
| Investigator site 0010191 | New York | New York | 10021 | — |
| Investigator site 0010074 | New York | New York | 10032 | — |
| Investigator site 0010075 | Patchogue | New York | 11772 | — |
| Investigator site 0010003 | Chapel Hill | North Carolina | 27517 | — |
| Investigator site 0010077 | Durham | North Carolina | 27710 | — |
| Investigator site 0010051 | Cincinnati | Ohio | 45267-0525 | — |
| Investigator site 0010064 | Columbus | Ohio | 43210 | — |
| Investigator site 0010047 | Philadelphia | Pennsylvania | 15213 | — |
| Investigator site 0010007 | Philadelphia | Pennsylvania | 19104 | — |
| Investigator site 0010067 | Pittsburgh | Pennsylvania | 15123 | — |
| Investigator site 0010066 | Austin | Texas | 78756 | — |
| Investigator site 0010026 | Houston | Texas | 77055-7421 | — |
| Investigator site 0010009 | San Antonio | Texas | 78229 | — |
| Investigator site 0010076 | Burlington | Vermont | 05401 | — |
| Investigator site 0010007 | Charlottesville | Virginia | 22903 | — |
| Investigator site 0010061 | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 171 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04281472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04281472 live on ClinicalTrials.gov.